Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy
JAMA Pediatr
.
2018 Jul 1;172(7):701.
doi: 10.1001/jamapediatrics.2018.0772.
Author
Randal Charles Richardson
1
Affiliation
1
Gillette Children's Specialty Healthcare, St Paul, Minnesota.
PMID:
29801053
DOI:
10.1001/jamapediatrics.2018.0772
No abstract available
Publication types
Letter
Comment
MeSH terms
Cost-Benefit Analysis
Humans
Morals
Muscular Atrophy, Spinal*
Oligonucleotides*
Substances
Oligonucleotides
nusinersen